Novartis receives third FDA approval for oral Fabhalta® (iptacopan)
Novartis announced that oral Fabhalta iptacopan has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G), to reduce proteinuria, making it the first and only treatment approved for this condition.